Poplar Therapeutics
PrivateLast Round
Series A
Extension
Mar 3, 2026
Total Funding Raised
$140M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Poplar Therapeutics Comparables
Compare Poplar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IgGenix | 81% | |
| Mabylon AG | 77% | |
| United BioPharma | 70% |
Poplar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 3, 2026 | ||||
| Series A | Jan 8, 2026 |
Poplar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A, Series A Extension |
| RA Capital Management | Series A, Series A Extension |
| Vida Ventures | Series A Extension, Series A |
| ArrowMark Partners | Series A, Series A Extension |
| Platanus Ventures | Series A |
| SR One | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
$45M round led by Janus Henderson Group.
- Jan 8, 2026
$50M Series A round completed.
Poplar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access